TSE:BHCBausch Health Companies Stock Price, Forecast & News

C$25.73

+0.13 (+0.51 %)

(As of 06/3/2020 04:00 PM ET)

Add

Compare

Today's Range

C$25.43

Now: C$25.73▼

C$26.22

50-Day Range

C$20.78

MA: C$24.21▼

C$26.03

52-Week Range

C$16.30

Now: C$25.73▼

C$42.15

Volume652,588 shs

Average Volume794,741 shs

Market CapitalizationC$9.09 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of C$28.00, Bausch Health Companies has a potential upside of 8.8% from its current price of C$25.73.
Amount of Analyst Coverage
Bausch Health Companies has received no research coverage in the past 90 days.

2.7 Community Rank

Outperform Votes
Bausch Health Companies has received 35 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Bausch Health Companies has received 29 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Bausch Health Companies has received 54.69% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Bausch Health Companies and other stocks. Vote “Outperform” if you believe BHC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BHC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Bausch Health Companies does not currently pay a dividend.
Dividend Growth
Bausch Health Companies does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bausch Health Companies insiders have not sold or bought any company stock.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Bausch Health Companies are expected to decrease by -100.00% in the coming year, from C$3.77 to C$0.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bausch Health Companies is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bausch Health Companies is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Bausch Health Companies has a PEG Ratio of 0.56. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Bausch Health Companies has a P/B Ratio of 12.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.79 out of 5 stars

Industry, Sector and Symbol

Stock Exchange TSE

Industry Drug Manufacturers - Specialty & Generic

Sub-IndustryN/A

SectorMedical

Current SymbolTSE:BHC

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.valeant.com

Phone514-744-6792

Debt

Debt-to-Equity Ratio3,092.15

Current Ratio1.13

Quick Ratio0.54

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio6.82

P/E Growth0.56

Sales & Book Value

Annual SalesC$8.60 billion

Price / Sales1.06

Cash FlowC$2.61 per share

Price / Cash Flow9.86

Book ValueC$2.03 per share

Price / Book12.69

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees21,100

Outstanding Shares353,356,000

Market CapC$9.09 billion

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive BHC News and Ratings via Email

Sign-up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.

Bausch Health Companies (TSE:BHC) Frequently Asked Questions

How has Bausch Health Companies' stock been impacted by COVID-19 (Coronavirus)?

Bausch Health Companies' stock was trading at C$25.34 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BHC shares have increased by 1.5% and is now trading at C$25.73. View which stocks have been most impacted by Coronavirus.

When is Bausch Health Companies' next earnings date?

Bausch Health Companies is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Bausch Health Companies.

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc (TSE:BHC) announced its quarterly earnings data on Thursday, May, 7th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.27 by $0.07. The firm had revenue of $2.70 billion for the quarter, compared to analyst estimates of $2.85 billion. View Bausch Health Companies' earnings history.

What price target have analysts set for BHC?

0 equities research analysts have issued 12-month price targets for Bausch Health Companies' shares. Their forecasts range from C$28.00 to C$28.00. On average, they anticipate Bausch Health Companies' share price to reach C$28.00 in the next year. This suggests a possible upside of 8.8% from the stock's current price. View analysts' price targets for Bausch Health Companies.

Has Bausch Health Companies been receiving favorable news coverage?

Media stories about BHC stock have been trending extremely negative on Wednesday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bausch Health Companies earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View the latest news aboutBausch Health Companies.

Who are some of Bausch Health Companies' key competitors?

Some companies that are related to Bausch Health Companies include Merck KGaA (MRK), Canopy Growth (WEED), Hikma Pharmaceuticals (HIK), Evotec (EVT), Aurora Cannabis (ACB), Aphria (APHA), Knight Therapeutics (GUD), Ecofibre (EOF), HLS Therapeutics (HLS), OrganiGram (OGI), Hexo (HEXO), Next Science (NXS), HEXO (HEXO), ICC Labs (ICC) and Amryt Pharma (AMYT). View all competitors.

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Chesapeake Energy (CHK), Aurora Cannabis (ACB), VolitionRX (VNRX), Bank of Nova Scotia (BNS), Enbridge (ENB), BlackBerry (BB), Baytex Energy (BTE), ARC Resources (ARX), Costco Wholesale (COST) and Surge Energy (SGY).

Who are Bausch Health Companies' key executives?

Bausch Health Companies' management team includes the following people:

Mr. Joseph C. Papa, CEO & Chairman (Age 64)
Mr. Paul S. Herendeen, Exec. VP & CFO (Age 63)
Ms. Christina M. Ackermann, Exec. VP & Gen. Counsel (Age 54)
Mr. Thomas J. Appio, Pres & Co-Head Bausch + Lomb/International (Age 57)
Mr. Joseph Gordon, Pres & Co-Head Bausch + Lomb/International (Age 55)

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the Toronto Stock Exchange (TSX) under the ticker symbol "BHC."

How do I buy shares of Bausch Health Companies?

Shares of BHC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately C$25.73.

How big of a company is Bausch Health Companies?

Bausch Health Companies has a market capitalization of C$9.09 billion and generates C$8.60 billion in revenue each year. Bausch Health Companies employs 21,100 workers across the globe.

What is Bausch Health Companies' official website?

The official website for Bausch Health Companies is www.valeant.com.

How can I contact Bausch Health Companies?

The company can be reached via phone at 514-744-6792.

This page was last updated on 6/3/2020 by MarketBeat.com Staff